The safety and efficacy of high-dose daptomycin combined with rifampicin for the treatment of Gram-positive osteoarticular infections
| Autor: | Ilker Uçkay, Kheeldass Jugun, Leonardo Pagani, Pierre Hoffmeyer, Jorge Garbino, Pierre Vaudaux, Daniel Pablo Lew |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male musculoskeletal diseases medicine.medical_specialty Prosthesis-Related Infections Daptomycin Osteoarthritis polycyclic compounds Humans Medicine Orthopedics and Sports Medicine In patient Prospective Studies Letter to the Editor Gram-Positive Bacterial Infections Aged Aged 80 and over ddc:616 Original Paper Surgical approach Dose-Response Relationship Drug ddc:617 business.industry Prosthetic joint infection Middle Aged Antimicrobial Anti-Bacterial Agents Surgery Regimen Treatment Outcome Orthopedic surgery Drug Therapy Combination Female Rifampin business Rifampicin Follow-Up Studies medicine.drug |
| Zdroj: | International Orthopaedics, Vol. 37, No 7 (2013) pp. 1375-80 |
| ISSN: | 0341-2695 |
| Popis: | Purpose: Treatment of Gram-positive osteoarticular infections requires an adequate surgical approach combined with intensive antimicrobial therapy. The aim of this study was to evaluate the safety and efficacy of a combined regimen of high-dose daptomycin and rifampicin, in patients with various types of Gram-positive osteoarticular infections. Methods: This single centre, non-comparative, prospective study evaluated the safety and efficacy of a combined regimen of intravenous daptomycin (8mg/kg/day) and oral rifampicin (600mg/day) in patients with Gram-positive osteoarticular infections, with a minimal follow-up of oneyear. Creatine phosphokinase, transaminases, bilirubinaemia, and serum creatinine, were measured at baseline and regular intervals. Results: The median daily doses of daptomycin and rifampicin, administered for a median duration of 21 (range, 10-122) days to 16 patients (median age, 63.5years; 11 males, five females) presenting with staphylococcal (n = 15) or streptococcal (n = 1) osteoarticular infections, were 8.15 (range, 6.6-8.9) mg/kg/day and 600 (range, 600-900) mg/day, respectively. The combined regimen of daptomycin and rifampicin was well tolerated by all except one patient, without requiring treatment adjustment or discontinuation. One patient developed allergic responses probably due to rifampicin after 42days. Fifteen (94%) patients showed favourable clinical and microbiological outcomes. Conclusions: The combined regimen of high-dose daptomycin and rifampicin was well tolerated and may provide a useful alternative to standard glycopeptide therapy for Gram-positive osteoarticular infections |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink